Healwell expands newly acquired CRO business into late-phase trials

Data science firm Healwell AI says its recently acquired CRO unit, BioPharma Services, will begin providing services for late-stage drug trials.

Toronto, Canada-based Healwell announced this week that it will integrate its existing research site, Canadian Phase Onward, into BioPharma’s early-phase trials business.

Healwell CEO Alexander Dobranowski said, “BioPharma is an industry leader in early phase trials, and integrating them with our CPO division immediately leverages our synergies to create a more robust and complete end-to-end platform for life science customers.”

Dobranowski added the plan is to use Healwell’s AI capabilities to “efficiently find at-risk patients in need of access to clinical research.”

This was echoed by Anna Taylor, managing director at BioPharma, who said, “We are excited about the integration of Canadian Phase Onward’s operation under BioPharma, which substantially enhances our clinical research capabilities as we expand our service offerings into late-stage patient trials.

“This integration not only broadens our reach into patient trials but also strengthens our capacity to deliver comprehensive clinical research services that are vital to our clients and the industry,” she said.

Post-acquisition plan

Healwell further specified that BioPharma will leverage AI technologies from its Khure Health and Pentavere Research Group units for patient identification.

In July, Healwell bought BioPharma from Think Research Corp. for $12.5 million, with the deal funded by a $20 million equity financing round completed in May.

The announced integration with CPO aligns with the post-acquisition plan Dobranowski shared at the time of the deal.

“We look forward to the collaborative potential and synergies expected to emerge from the integration of these new acquisitions with our existing business units.

“We now have the tools to help large enterprises such as provincial health systems to not only better manage their health data but apply artificial intelligence to conduct next-generation population health and value-based care strategies at scale,” he said.

Unsplash/BoliviaInteligente